Asthma | Control | ||||
Mild | Moderate | Severe | Total | ||
Aas Score | 1–2 | 3 | 4–5 | ||
Subjects n | 27 | 6 | 8 | 41 | 17 |
Viability % | 57.4±3.5 | 62±9.7 | 71.6±5.1 | 61.2±3.0 | 63.6±3.7 |
Nonsquamous cells ×105·mL−1 | 6.1±0.9 | 6.4±1.8 | 5.7±1.8 | 6.1±0.72 | 1.93±0.52# |
Total eosinophils ×105·mL−1 | 0.55 (0.25–1.0) | 0.88 (0.84–1.2) | 2.24 (0.84–4.18)¶ | 0.8 (0.4–1.2) | 0.02 (0–0.05)+ |
Squamous contamination % | 3.1 (1.6–8.9) | 10.9 (4.4–13.7) | 1.9 (0.6–9.7) | 3.1 (1.5–10.0) | 6.9 (3.1–25.0) |
Sputum eosinophils % | 7.4 (3.5–24.7) | 34.5 (16.6–38.8)§ | 50.5 (46.5–62.0)ƒ | 20.4 (6.5–44) | 2 (0.5–3.0)## |
AR | 0.80 (0.65–0.94) | 0.62 (0.36–0.68)¶¶ | 0.49 (0.13–0.56)++ | 0.69 (0.49–0.89) | 0.98 (0.97–0.99)§§ |
EG2+ve eosinophils % | 31 (22.6–43.3) | 26.5 (22.8–33.0) | 31 (26.3–38.0) | 31 (22.0–40.5) | 1 (0–6.0)ƒƒ |
Data presented as mean±sem or median (IQR) unless otherwise stated
AR: apoptotic ratio
#: p<0.0001, asthma versus control (95% confidence interval (95% CI) 1.8–6.5)
¶: p<0.05, severe versus mild (95% CI 0.28–3.44)
+: p<0.0001, asthma versus control (95% CI 0.47–1.0)
§: p<0.05, moderate versus mild (95% CI 11.0–36.0)
ƒ: p<0.0005, severe versus mild (26.6–48.8)
##: p<0.0001, asthma versus control (95% CI 5.5–35.0)
¶¶: p<0.05, moderate versus mild (95% CI 0.032–0.395)
++: p<0.005, severe versus mild (CI 0.21–0.57)
§§: p<0.0001 asthma versus control (95% CI 0.146–0.414)
ƒƒ: p<0.0001 asthma versus control (95% CI 20.2–33.9)